Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Lung cancer is a common cause of morbidity and mortality, and even with modern imaging, lung cancer staging is inadequate. Involved regional lymph nodes often are not detected and are subsequently ignored at the time of definitive surgery or radiation. This may lead to regional failures in otherwise curable patients. Our goal is to identify the primary lymph node drainage of lung cancer. With the results of this research, management could be more customized to individual patient circumstances, potentially improving outcomes.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Lawrence "Rusty" Hofmann, MD
- Quynh-Thu Le, MD, FACR, FASTRO
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- Ann Leung
- Daniel Sze, MD, PhD
- Billy W. Loo, Jr., MD, PhD, DABR
- Nishita Kothary, MD
- Heather Wakelee, MD
- device : True Beam
- device : Cyberknife
- device : Trilogy
- drug : Iohexol
- procedure : Stereotactic Body Radiation Therapy (SBRT)
- radiation : Computed Tomography (CT)
Ages Eligible For Study:
- Either 1. Established primary lung cancer/ cancer metastatic to lung, OR 2. Lesion suspicious for malignancy in lung, according to the following criteria: A. Histopathologically confirmed lung cancer or cancer metastatic to lung, OR B. Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR C. Known metastatic cancer, with metastases to the lung based on imaging - Age > 18 years old - Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix IV) - No prior surgery, chemotherapy, or radiation for the current lung tumor - Both men and women and members of all races and ethnic groups are eligible for this trial.